Publications by authors named "Richard A Van Etten"

69Publications

Chronic Myeloproliferative Neoplasms: Some Remaining Challenges.

Hemasphere 2018 10 2;2(5):e147. Epub 2018 Oct 2.

University of California Irvine, Irvine, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/HS9.0000000000000147DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6407801PMC
October 2018

Distinct GAB2 signaling pathways are essential for myeloid and lymphoid transformation and leukemogenesis by BCR-ABL1.

Blood 2016 Apr 15;127(14):1803-13. Epub 2016 Jan 15.

Molecular Oncology Research Institute, Tufts Medical Center, Boston, MA; Program in Molecular and Cellular Physiology, Sackler School of Graduate Biomedical Sciences, Tufts University School of Medicine, Boston, MA;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2015-06-653006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4825414PMC
April 2016

In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.

Authors:
Ayalew Tefferi Hagop Kantarjian S Vincent Rajkumar Lawrence H Baker Jan L Abkowitz John W Adamson Ranjana Hira Advani James Allison Karen H Antman Robert C Bast John M Bennett Edward J Benz Nancy Berliner Joseph Bertino Ravi Bhatia Smita Bhatia Deepa Bhojwani Charles D Blanke Clara D Bloomfield Linda Bosserman Hal E Broxmeyer John C Byrd Fernando Cabanillas George Peter Canellos Bruce A Chabner Asher Chanan-Khan Bruce Cheson Bayard Clarkson Susan L Cohn Gerardo Colon-Otero Jorge Cortes Steven Coutre Massimo Cristofanilli Walter J Curran George Q Daley Daniel J DeAngelo H Joachim Deeg Lawrence H Einhorn Harry P Erba Francisco J Esteva Elihu Estey Isaiah J Fidler James Foran Stephen Forman Emil Freireich Charles Fuchs James N George Morie A Gertz Sergio Giralt Harvey Golomb Peter Greenberg Jordan Gutterman Robert I Handin Samuel Hellman Paulo Marcelo Hoff Ronald Hoffman Waun Ki Hong Mary Horowitz Gabriel N Hortobagyi Clifford Hudis Jean Pierre Issa Bruce Evan Johnson Philip W Kantoff Kenneth Kaushansky David Khayat Fadlo R Khuri Thomas J Kipps Margaret Kripke Robert A Kyle Richard A Larson Theodore S Lawrence Ross Levine Michael P Link Scott M Lippman Sagar Lonial Gary H Lyman Maurie Markman John Mendelsohn Neal J Meropol Yoav Messinger Therese M Mulvey Susan O'Brien Roman Perez-Soler Raphael Pollock Josef Prchal Oliver Press Jerald Radich Kanti Rai Saul A Rosenberg Jacob M Rowe Hope Rugo Carolyn D Runowicz Brenda M Sandmaier Alan Saven Andrew I Schafer Charles Schiffer Mikkael A Sekeres Richard T Silver Lillian L Siu David P Steensma F Marc Stewart Wendy Stock Richard Stone Rainer Storb Louise C Strong Martin S Tallman Michael Thompson Naoto T Ueno Richard A Van Etten Julie M Vose Peter H Wiernik Eric P Winer Anas Younes Andrew D Zelenetz Charles A LeMaistre

Mayo Clin Proc 2015 Aug 23;90(8):996-1000. Epub 2015 Jul 23.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.mayocp.2015.06.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5365030PMC
August 2015

Loss of Ikaros DNA-binding function confers integrin-dependent survival on pre-B cells and progression to acute lymphoblastic leukemia.

Nat Immunol 2014 Mar 9;15(3):294-304. Epub 2014 Feb 9.

Cutaneous Biology Research Center, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ni.2821DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4494688PMC
March 2014

IKK-dependent activation of NF-κB contributes to myeloid and lymphoid leukemogenesis by BCR-ABL1.

Blood 2014 Apr 24;123(15):2401-11. Epub 2014 Jan 24.

Molecular Oncology Research Institute, Tufts Medical Center, Boston, MA;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2014-01-547943DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3983614PMC
April 2014

Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity.

Oncoimmunology 2013 Oct 22;2(10):e26527. Epub 2013 Oct 22.

Molecular Oncology Research Institute; Tufts Medical Center; Boston, MA USA ; Division of Hematology/Oncology; Tufts Medical Center; Boston, MA USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/onci.26527DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3881109PMC
October 2013

Selectins and their ligands are required for homing and engraftment of BCR-ABL1+ leukemic stem cells in the bone marrow niche.

Blood 2014 Feb 6;123(9):1361-71. Epub 2014 Jan 6.

Division of Hematology/Oncology and Molecular Oncology Research Institute, Tufts Medical Center, Boston, MA;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2013-11-538694DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3938148PMC
February 2014

Alternative approaches to eradicating the malignant clone in chronic myeloid leukemia: tyrosine-kinase inhibitor combinations and beyond.

Hematology Am Soc Hematol Educ Program 2013 ;2013:189-200

1Division of Hematology/Oncology and Molecular Oncology Research Institute, Tufts Medical Center, Boston, MA; and.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2013.1.189DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4529996PMC
December 2014

Differential regulation of myeloid leukemias by the bone marrow microenvironment.

Nat Med 2013 Nov 27;19(11):1513-7. Epub 2013 Oct 27.

1] Center for Regenerative Medicine and Cancer Center, Massachusetts General Hospital, Boston, Massachusetts, USA. [2] Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, Massachusetts, USA. [3] Harvard Stem Cell Institute, Cambridge, Massachusetts, USA. [4] Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nm.3364DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3827980PMC
November 2013

Signal transduction in the chronic leukemias: implications for targeted therapies.

Curr Hematol Malig Rep 2013 Mar;8(1):71-80

Molecular Oncology Research Institute and Division of Hematology/Oncology, Tufts Medical Center, 800 Washington Street, Box 5609, Boston, MA 02111, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-012-0150-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3886724PMC
March 2013

New insights into the normal and leukemic stem cell niche: a timely review.

Cytometry B Clin Cytom 2013 Jan-Feb;84(1):5-6

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cyto.b.21071DOI Listing
June 2013

BCL6: a novel target for therapy of Ph+ B cell acute lymphoblastic leukemia.

Cancer Cell 2011 Jul;20(1):3-5

Molecular Oncology Research Institute, Division of Hematology/Oncology, Tufts Medical Center, Boston, MA 02111, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccr.2011.06.021DOI Listing
July 2011

Navigating the road toward optimal initial therapy for chronic myeloid leukemia.

Curr Opin Hematol 2011 Mar;18(2):89-97

Division of Hematology/Oncology, Tufts Medical Center, Boston, Massachusetts 02111, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOH.0b013e32834399a5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3496274PMC
March 2011

GCK is essential to systemic inflammation and pattern recognition receptor signaling to JNK and p38.

Proc Natl Acad Sci U S A 2009 Mar 25;106(11):4372-7. Epub 2009 Feb 25.

The Molecular Cardiology Research Institute, and Department of Medicine, Tufts University School of Medicine, Boston, MA 02111, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.0812642106DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2657458PMC
March 2009

Murine retroviral bone marrow transplantation models for the study of human myeloproliferative disorders.

Curr Protoc Pharmacol 2008 Dec;Chapter 14:Unit14.10

Molecular Oncology Research Institute, Tufts Medical Center, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/0471141755.ph1410s43DOI Listing
December 2008

Production of replication-defective retrovirus by transient transfection of 293T cells.

J Vis Exp 2007 4(10):550. Epub 2007 Dec 4.

Molecular Oncology Research Institute, Tufts-NEMC, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3791/550DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2557082PMC
February 2009

Suppression of E-protein activity interferes with the development of BCR-ABL-mediated myeloproliferative disease.

Proc Natl Acad Sci U S A 2008 Sep 25;105(35):12967-72. Epub 2008 Aug 25.

Division of Biological Sciences, University of California at San Diego, La Jolla, CA 92093, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.0805073105DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2529058PMC
September 2008

Peroxiredoxin1 prevents excessive endothelial activation and early atherosclerosis.

Circ Res 2008 Sep 8;103(6):598-605. Epub 2008 Aug 8.

Immune Disease Institute and Department of Pathology, Harvard Medical School, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1161/CIRCRESAHA.108.174870DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4911701PMC
September 2008

Right on target: eradicating leukemic stem cells.

Trends Mol Med 2007 Nov 5;13(11):470-81. Epub 2007 Nov 5.

Department of Pathology, Massachusetts General Hospital, Boston, MA 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molmed.2007.09.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4344828PMC
November 2007

Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition.

Nat Rev Cancer 2007 May;7(5):332-44

Center for Translational Medicine and Cardiology Division, Department of Medicine, Thomas Jefferson University, 1025 Walnut Street, Philadelphia, PA 19107, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrc2106DOI Listing
May 2007

Oncogenic signaling: new insights and controversies from chronic myeloid leukemia.

J Exp Med 2007 Mar 12;204(3):461-5. Epub 2007 Mar 12.

Molecular Oncology Research Institute and the Division of Hematology/Oncology, Tufts-New England Medical Center, Boston, MA 02111, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1084/jem.20062335DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2137897PMC
March 2007

Ubiquitous and uniform in vivo fluorescence in ROSA26-EGFP BAC transgenic mice.

Genesis 2007 Feb;45(2):83-9

Division of Gastroenterology, GRASP Digestive Disease Center, Tufts-New England Medical Center, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/dvg.20269DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2121618PMC
February 2007

Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F.

PLoS One 2006 Dec 20;1:e18. Epub 2006 Dec 20.

Molecular Oncology Research Institute, Tufts-New England Medical Center, Boston, Massachusetts, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0000018PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1762384PMC
December 2006

Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells.

Nat Med 2006 Oct 24;12(10):1175-80. Epub 2006 Sep 24.

Molecular Oncology Research Institute, Tufts-New England Medical Center, 750 Washington Street, Boston, Massachusetts 02111, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nm1489DOI Listing
October 2006

Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

Nat Med 2006 Aug 23;12(8):908-16. Epub 2006 Jul 23.

Center for Translational Medicine, Jefferson Medical College, 1025 Walnut Street, Philadelphia, Pennsylvania 19107, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nm1446DOI Listing
August 2006

Tyrosine kinases as targets for cancer therapy.

N Engl J Med 2005 Jul;353(2):172-87

Molecular Oncology Research Institute, Division of Hematology-Oncology, Tufts-New England Medical Center, Boston, MA 02111, USA.

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/abs/10.1056/NEJMra044389
Publisher Site
http://dx.doi.org/10.1056/NEJMra044389DOI Listing
July 2005

JAKing up hematopoietic proliferation.

Cancer Cell 2005 Apr;7(4):291-3

Department of Pediatrics and Comprehensive Cancer Center, University of California, San Francisco, California 94143, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccr.2005.04.002DOI Listing
April 2005

Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptor.

Blood Cells Mol Dis 2005 Mar-Apr;34(2):181-5

Medizinische Klinik für Hämatologie und Onkologie, Campus Virchow, Charité, Humboldt Universität, Augustenburger Platz 1, 13353 Berlin, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bcmd.2004.11.006DOI Listing
September 2005

Focus on myeloproliferative diseases and myelodysplastic syndromes.

Cancer Cell 2004 Dec;6(6):547-52

Molecular Oncology Research Institute, Tufts-New England Medical Center, Boston, MA 02111, USA.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S153561080400341
Publisher Site
http://dx.doi.org/10.1016/j.ccr.2004.12.004DOI Listing
December 2004

Adoptive immunotherapy of BCR-ABL-induced chronic myeloid leukemia-like myeloproliferative disease in a murine model.

Blood 2004 Dec 12;104(13):4236-44. Epub 2004 Aug 12.

Center for Blood Research, Institute for Biomedical Research, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/cgi/doi/10.1182/blood-2004-06-22
Publisher Site
http://dx.doi.org/10.1182/blood-2004-06-2229DOI Listing
December 2004

A direct binding site for Grb2 contributes to transformation and leukemogenesis by the Tel-Abl (ETV6-Abl) tyrosine kinase.

Mol Cell Biol 2004 Jun;24(11):4685-95

Molecular Oncology Research Institute, Tufts-New England Medical Center, 750 Washington St., Box 5609, Boston, MA 02111, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1128/MCB.24.11.4685-4695.2004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC416425PMC
June 2004

Mechanisms of transformation by the BCR-ABL oncogene: new perspectives in the post-imatinib era.

Leuk Res 2004 May;28 Suppl 1:S21-8

Molecular Oncology Research Institute, Tufts-New England Medical Center, 750 Washington Street, Boston, MA 02111, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2003.10.005DOI Listing
May 2004

c-Abl regulation: a tail of two lipids.

Curr Biol 2003 Aug;13(15):R608-10

The Center for Blood Research, Harvard Medical School, 200 Longwood Avenue, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0960-9822(03)00528-1DOI Listing
August 2003

Essential role for the peroxiredoxin Prdx1 in erythrocyte antioxidant defence and tumour suppression.

Nature 2003 Jul;424(6948):561-5

Center for Blood Research and Department of Genetics, Harvard Medical School, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nature01819DOI Listing
July 2003

Autoinhibition of Bcr-Abl through its SH3 domain.

Mol Cell 2003 Jul;12(1):27-37

The Center for Blood Research and Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s1097-2765(03)00274-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7128750PMC
July 2003

Studying the pathogenesis of BCR-ABL+ leukemia in mice.

Oncogene 2002 Dec;21(56):8643-51

The Center for Blood Research and Department of Genetics, Harvard Medical School, Boston, Massachusetts, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/sj.onc.1206091DOI Listing
December 2002

Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop.

Proc Natl Acad Sci U S A 2002 Aug 29;99(16):10700-5. Epub 2002 Jul 29.

Center for Blood Research and Department of Genetics, Harvard Medical School, 200 Longwood Avenue, Boston, MA 02115-5717, USA.

View Article

Download full-text PDF

Source
http://www.pnas.org/cgi/doi/10.1073/pnas.162140299
Publisher Site
http://dx.doi.org/10.1073/pnas.162140299DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC125018PMC
August 2002

Critical role for Gab2 in transformation by BCR/ABL.

Cancer Cell 2002 Jun;1(5):479-92

Dana-Farber Cancer Institute, Department of Adult Oncology, Harvard Medical School, 44 Binney Street, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s1535-6108(02)00074-0DOI Listing
June 2002

Tyrosine phosphorylation of Mdm2 by c-Abl: implications for p53 regulation.

EMBO J 2002 Jul;21(14):3715-27

Lautenberg Center for General and Tumor Immunology, The Hebrew University Hadassah Medical School, Jerusalem 91120, Israel.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/emboj/cdf384DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC125401PMC
July 2002

The Tel-Abl (ETV6-Abl) tyrosine kinase, product of complex (9;12) translocations in human leukemia, induces distinct myeloproliferative disease in mice.

Blood 2002 Jun;99(12):4568-77

The Center for Blood Research and Department of Genetics, Brigham and Women's Hospital, Harvard Institutes of Medicine, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2001-12-0244DOI Listing
June 2002